Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BARDA awards contracts to develop drugs for acute radiation syndrome
The contracts are part of an ongoing effort to develop diagnostic tools and drugs to protect health and save lives in a radiological or nuclear emergency such as
The contracts are part of an ongoing effort to develop diagnostic tools and drugs to protect health and save lives in a radiological or nuclear emergency such as
The company expects to recruit patients in 70 centers in 11 European nations. In the trial, the preterm infants younger than 32 weeks of gestational age are randomized
Ridaforolimus is an investigational mTOR inhibitor being developed by Merck that has completed a Phase 3 clinical trial in patients with soft-tissue and bone sarcomas and is being
Livatag, which has been awarded orphan drug status in Europe and US, is a treatment presented in nanoparticles able to deliver doxorubicin in chemoresistant cells. The production for
The products include Neo-Polycin; Neo-Polycin HC; Polycin; Neomycin and Polymyxin B Sulfates with Dexamethasone Ophthalmic Ointments. Fera president Frank DellaFera said achieving this important milestone for their company,
Capsugel is a provider of drug delivery systems for the pharmaceutical, OTC and health and nutrition industries. Capsugel provides array of products and services, from hard gelatin, vegetarian
StayinFront is a global provider of CRM systems and mobile sales force effectiveness tools. Using StayinFront CRM systems, which run on AdvantageMS National Provider Database, users can have
ALN-VSP is a systemically delivered RNAi therapeutic which includes two siRNAs intended to target two genes critical for the growth and development of cancer cells: vascular endothelial growth
Kodiac program includes two placebo controlled randomized Phase III studies and a randomized, open-label, placebo-controlled long term safety study. The two studies are designed to investigate the safety,
The solution, which will be launched as a generic in 100 milligrams per 5ml (20 milligrams per 1 ml), is intended to relieve moderate to severe acute and